Value in Health 2013-12-01

Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.

Sukhvinder Johal, Stephen Ralston, Christopher Knight

Index: Value Health 16(8) , 1123-32, (2013)

Full Text: HTML

Abstract

Mifamurtide is an immune macrophage stimulant that when added to standard chemotherapy has demonstrated survival benefit for newly diagnosed osteosarcoma. The objectives of this study were to investigate the cost-effectiveness of adding mifamurtide to standard three- or four-agent chemotherapy for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection and the issues of obtaining robust cost-effectiveness estimates for ultra-orphan drugs, given the shortage of data.

Related Compounds

Related Articles:

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

2009-08-01

[Expert Rev. Anticancer Ther. 9(8) , 1035-49, (2009)]

Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.

2008-09-01

[Parasitol. Res. 103(4) , 919-29, (2008)]

In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.

1999-04-01

[Cancer Biother. Radiopharm. 14(2) , 121-8, (1999)]

Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.

1998-10-01

[Cancer Biother. Radiopharm. 13(5) , 363-8, (1998)]

Effect of MTP on TNF-alpha in perfused rat liver after bacteremia and ischemia/reperfusion.

1998-05-01

[J. Surg. Res. 76(2) , 179-84, (1998)]

More Articles...